BRIEF published on 11/26/2025 at 00:51, 7 months 16 days ago CureVac Announces Results of Extraordinary General Meeting BioNTech Extraordinary General Meeting CureVac Shareholders Approval Legal Merger
PRESS RELEASE published on 11/26/2025 at 00:46, 7 months 16 days ago CureVac Announces Voting Results of Extraordinary General Meeting CureVac announces approval of BioNTech's exchange offer for outstanding shares at Extraordinary General Meeting with over 99.16% approval rate BioNTech MRNA Technology Exchange Offer CureVac EGM Voting Results
BRIEF published on 11/24/2025 at 13:15, 7 months 17 days ago CureVac Reports Q3 and Nine-Month Financial Results for 2025 Financial Performance MRNA Technology CureVac Q3 2025 Results BioNTech Merger
PRESS RELEASE published on 11/24/2025 at 13:10, 7 months 17 days ago CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates CureVac announces financial results for Q3 and first nine months of 2025, BioNTech transaction progresses, EMA clearance received for cancer therapy CVHNLC sqNSCLC Financial Results Cancer Therapy CureVac BioNTech Transaction EMA Clearance
BRIEF published on 08/15/2025 at 13:32, 10 months 27 days ago CureVac Reports Q2 and H1 2025 Financial Results; Announces Key Developments Financial Results MRNA Technology CureVac Patent Resolution BioNTech Acquisition
PRESS RELEASE published on 08/15/2025 at 13:27, 10 months 27 days ago CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates CureVac announces Q2 2025 financial results, business updates & agreement with BioNTech for transformative mRNA treatments. Strong cash position Financial Results BioNTech CureVac MRNA Q2 2025
BRIEF published on 08/08/2025 at 02:20, 11 months 4 days ago CureVac Settles Patent Dispute with Pfizer/BioNTech MRNA Technology CureVac Pfizer/BioNTech Patent Resolution Vaccine Royalties
PRESS RELEASE published on 08/08/2025 at 02:15, 11 months 4 days ago CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech CureVac resolves patent litigation with Pfizer/BioNTech related to mRNA-based COVID-19 vaccines, receiving $790 million and non-exclusive license agreements BioNTech MRNA Technology CureVac Patent Litigation Pfizer
BRIEF published on 06/24/2025 at 22:14, 1 year ago CureVac Reports Outcomes of Annual General Meeting MRNA Technology Annual Meeting Board Appointments Auditors CureVac
PRESS RELEASE published on 06/24/2025 at 22:09, 1 year ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of Annual General Meeting, including new Management Board and Supervisory Board appointments. KPMG reappointed as external auditors Annual General Meeting Appointments Voting Results KPMG CureVac
Published on 07/11/2026 at 02:50, 1 day 4 hours ago Alaska Energy Metals Reports on At-the-Market Equity Financing Program
Published on 07/11/2026 at 02:00, 1 day 4 hours ago Battery X Metals Presents Positive Preliminary Lithium-Ion Battery Rebalancing Trial Results Demonstrating Significant Estimated Driving Range Improvements and Accelerated Commercialization Progress of its Patent-Pending Lithium-Ion Battery Rebalancing Te
Published on 07/11/2026 at 02:00, 1 day 4 hours ago Discovery Energy Metals Announces Non-Brokered Private Placement Financing
Published on 07/11/2026 at 00:00, 1 day 6 hours ago Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010’s API
Published on 07/11/2026 at 04:00, 1 day 2 hours ago CUHK Achieves Top 20 Global Ranking in QS World University Rankings 2027
Published on 07/10/2026 at 18:40, 1 day 12 hours ago AFX Surpasses $1.1 Billion in Total Trading Volume, Highlighting Capital Efficiency in On-Chain Derivatives
Published on 07/10/2026 at 17:45, 1 day 13 hours ago WYF Launches Global AI Talent Compact at AI for Good Global Summit 2026
Published on 07/10/2026 at 17:14, 1 day 13 hours ago Form 8.3 - SAFESTAY PLC: Opening Position Disclosure
Published on 07/10/2026 at 18:00, 1 day 12 hours ago Half-year liquidity contract statement for CEGEDIM
Published on 07/10/2026 at 10:34, 1 day 20 hours ago Number of shares and voting rights - June 2026 (In French only)
Published on 07/09/2026 at 18:00, 2 days 12 hours ago Second-quarter 2026 activity: +7% (vs. Q2 2025)
